Meibomian Gland Disease Meibomian gland disease MGD Dry eye
Conditions
Interventions
Being diagnosed of bagging lower eyelids and any stage of MGD
Treatment
Patient with MGD and baggy lower eyelid
Sponsors
Bumrungrad International Hospital
Department of Dermatology,
Faculty of Medicine,
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.Age more than or equal to 18 years 2. Clinially diagnosed with any stage of MGD with OSDI more than 12 or meibum quality score more than 1
Exclusion criteria
Exclusion criteria: 1) Blindness or having one eye 2) Having a history of glaucoma which required topical anti-glaucoma treatment 3) Having a history of glaucoma and retinal intraocular surgery or lid surgery 4) Having a history of ocular herpes within prior 3 months 5) Having an active ocular inflammation or infection 6) Having eyelid or ocular surface diseases 7) Having systemic disease(s) causing dry eye / delayed wound healing 8) Contact lens wearer 9) Having abnormal scarring at laser treatment site 10) Infection or inflammation of treatment area 11) Prone to excessive sunlight exposure (tanned skin), which was darker than natural skin face tone within 2 weeks after the procedure [eg., outdoor occupation (farming, aerobic trainer), outdoor sport player, regular beach goers, etc.] 12) Having a history of photosensitivity or use of photosensitizing medication 13) Being pregnancy 14) Having uncontrolled diabetes, heart and lung disease, or hypertension 15) Known of cancer in the area to be treated 16) Having autoimmune disorder(s) 17) Having herpes simplex infection in the treatment area 18) Having collagen, scarring and connective tissue disorders 19) Having clotting disorders 20) Having wound healing disorders 21) Having or known of Epilepsy 22) Having used Retin-A or similar products 3 days before and 7 days after treatment 23) Having used Accutane (Roaccutane) within 6 months 24) Having used Systemic antifungal, oral antifungal therapy, or isotretinoin within 6 months 25) Ever used Gold therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Meibum quality score baseline, at 16-20 week, at 24-28week follow-up Meibum quality was assessed after force was applied to the eyelids via the Meibomian Gland Evaluator | — |
Secondary
| Measure | Time frame |
|---|---|
| Ocular Surface Index Score baseline, at 16-20 week, at 24-28week follow-up a 12-item questionnaire designed to provide a rapid assessment of: symptoms of ocular irritation con,Tear break-up time baseline, at 16-20 week, at 24-28week follow-up TBUT was performed using the pre-cut 2% sodium fluorescein strip (Ophthalmic Technology Pvt. Ltd., I,lipid layer thickness (TFLLT) baseline, at 16-20 week, at 24-28week follow-up We used the tear film interferometer (LipiView II ®Ocular Surface Interferometer (TearScience)) to ,Oxford Scheme Grade baseline, at 16-20 week, at 24-28week follow-up The Oxford scheme grade was obtained under cobalt-blue light after fluorescein staining. To grade th,Meibography baseline, at 16-20 week, at 24-28week follow-up We performed meibography to get a meiboscore using a Keratograph 5M (OCULUS, Wetzlar, Germany). This,UCVA baseline, at 16-20 week, at 24-28week follow-up All participants was assessed by visual analog scale. | — |
Contacts
Public ContactNgamjit Kasetsuwan
Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Me
Outcome results
None listed